Document is current
Any future updates will be listed below
-
Authors
Finnsson, Eysteinn https://orcid.org/0000-0001-7396-0713
Erlingsson, Ernir https://orcid.org/0000-0003-2867-6291
Hlynsson, Hlynur D. https://orcid.org/0000-0002-9487-8054
Valsdóttir, Vaka https://orcid.org/0000-0003-3642-6313
Sigmarsdottir, Thora B. https://orcid.org/0000-0002-4737-4646
Arnardóttir, Eydís https://orcid.org/0000-0002-9245-5779
Sands, Scott A. https://orcid.org/0000-0003-3752-0328
Jónsson, Sigurður Æ https://orcid.org/0009-0004-7765-4018
Islind, Anna S. https://orcid.org/0000-0002-4563-0001
Ágústsson, Jón S. https://orcid.org/0000-0003-4309-6439
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL146697, R01HL168067)
American Academy of Sleep Medicine Foundation (228-SR-20)
- License Information
-
More Information
Article History
Received: 19 December 2024
Revised: 24 February 2025
Accepted: 2 April 2025
First Online: 11 April 2025
Declarations
:
: The study was deemed exempt from institutional review board (IRB) review by the WCG IRB under 45 CFR § 46.104(d)(4), as the data involved did not allow for the direct identification or re-identification of human subjects.
: During the preparation of this work the author(s) used OpenAI’s ChatGPT 4o to suggest improvements in language and readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
: Eysteinn Finnsson, Ernir Erlingsson, Hlynur D. Hlynsson, Vaka Valsdóttir, Thora B. Sigmarsdottir, Eydís Arnardóttir, Sigurður Æ. Jónsson, and Jón S. Ágústsson are all employees of Nox Medical.Scott A. Sands received grant support from Apnimed, Prosomnus, and Dynaflex, and has served as a consultant for Apnimed, Nox Medical, Inspire Medical Systems, Eli Lilly, Respicardia, LinguaFlex, and Forepont. He receives royalties for intellectual property pertaining to combination pharmacotherapy for sleep apnea via his Institution. He is also co-inventor of intellectual property pertaining to wearable sleep apnea phenotyping, also via his Institution. His industry interactions are actively managed by his Institution.Anna S. Islind has no competing interests to declare.
